Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Maria Chiara Scali , Doralisa Morrone , Mario Marzilli Added: 3 years ago
As coronary angiography is of limited value in defining the functional significance of a stenosis, the timely article by Balanescu in this issue of European Cardiology Review rationally proposes to integrate the anatomic information with a functional assessment, either by measuring coronary flow reserve (CFR) or intracoronary artery pressure with fractional flow reserve (FFR). CFR measurements… View more
Author(s): Serban Balanescu Added: 3 years ago
Coronary artery disease (CAD) due to atherosclerosis is a major cause of morbidity and mortality. Early prevention of atherothrombotic disease with a healthy lifestyle (diet, exercise, optimal body weight and no smoking) is considered the best method of “treating” CAD, although increasing age remains associated with significant cardiovascular events. When coronary atherothrombotic disease… View more
Author(s): Rikuta Hamaya , Yoshihisa Kanaji , Eisuke Usui , et al Added: 3 years ago
Clinical and economic benefits of fractional flow reserve (FFR)-guided revascularisation have been established and the strategy is a class-1 recommendation in current guidelines.1,2 FFR values both before and after percutaneous coronary intervention (PCI) have been reported to provide prognostic information.3–5 Originally, FFR was used as a surrogate measure of impaired coronary flow, and… View more
Author(s): Valérie E Stegehuis , Gilbert WM Wijntjens , Tadashi Murai , et al Added: 3 years ago
The emphasis in ischaemic heart disease (IHD) diagnosis has historically been directed towards the identification of epicardial coronary stenosis by selective coronary angiography, and its management by percutaneous coronary intervention (PCI) or coronary bypass graft surgery. Over the past two decades, the application of coronary physiology techniques to identify the haemodynamic severity of… View more
Author(s): Nicolas M Van Mieghem , Joost Daemen Added: 2 years ago
In this concise episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their analysis of the late-breaking trials that will be presented at ACC 2022. Trials covered in detail include: 00:39: PACMAN AMI: Effects of Alirocumab on Coronary Atherosclerosis Assessed by Serial Multimodality Intracoronary Imaging in Patients… View more